ZD1839 (Iressaâ„¢) In Combination With Docetaxel As First-Line Treatment In Patients With Metastatic Breast Cancer
This is a multicentre, randomised (2:1), double blind, non-comparative phase II trial of ZD1839 and placebo in combination with chemotherapy in patients with metastatic breast cancer.
Breast Cancer
DRUG: Gefitinib|DRUG: Docetaxel
To estimate the overall response rates (complete response [CR] and partial response [PR]) in the ZD1839-treated group and the placebo-treated group.
o To assess progression-free survival (PFS) in the ZD1839-treated group and the placebo-treated group.|o To estimate the duration of response in the ZD1839-treated group and the placebo treated group|o To estimate overall survival in the ZD1839-treated group and the placebo-treated group|o To estimate time to treatment failure (TTF) in the ZD1839-treated group and the placebo treated group
This is a multicentre, randomised (2:1), double blind, non-comparative phase II trial of ZD1839 and placebo in combination with chemotherapy in patients with metastatic breast cancer.